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Abstract - The aim of this study is to determine the prevalence of extended spectrum beta-lactamase (ESBL) producing 
Klebsiella pneumoniae strains isolated from blood in children and their susceptibility to antimicrobial drugs commonly 
used in the therapy. The study was conducted at the Institute of Public Health of Vojvodina Province, Serbia, in a two-year 
period, from January 2009 to December 2010. A total of 424 non-duplicate strains were isolated from the blood of pediat-
ric patients hospitalized in various wards in the Institute of Health Care of Children and Youth of Vojvodina Province. Fifty 
isolates of Klebsiella pneumoniae were reported. The frequency of isolation of Klebsiella pneumoniae was 27/222 (12.2%) 
and 23/202 (11.3%) isolates in 2009 and 2010, respectively. There was a high prevalence of ESBL-producing Klebsiella 
pneumoniae, 76% (38/50), and 17 isolates (44.7%) were multidrug resistant (MDR). Further drug resistance surveillance 
in hospitals and the molecular characterization of ESBL-positive isolates in our country is necessary.
Key words: Klebsiella pneumoniae, bloodstream infection, antimicrobial resistance, extended spectrum beta lactamase 
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INTRODUCTION
Symptomatic  bacteremia  is  a  common  condition 
in children and requires urgent rational antibiotics 
therapy. It is also a significant cause of high morbid-
ity and mortality (Ogunleye et al., 2005). 
Klebsiella  pneumoniae,  a  gram-negative  bac-
terium,  was  the  most  common  causative  agents 
in pediatric bloodstream infection (Arnoni et al., 
2007). Risk factors for colonization and infection 
are recent surgery, central venous catheters, trache-
otomy, parenteral nutrition, and uncontrolled use 
of  broad-spectrum  antibiotics  (third  generation 
cephalosporins,  fluoroquinolones,  carbapenems). 
Reservoirs of infection are the intestinal and respi-
ratory tracts of hospitalized patients and hospital 
staff, and the way of transmissions is by the hands 
of the staff or contaminated medical equipment and 
fluids (Zakaria et al., 2008). 
Due to the irrational use of antibiotics, K. pneu-
moniae isolated from blood culture is mostly multi-
drug resistant (resistant to three or more antibiotic 
classes), often producing beta-lactamases (Kang et 
al., 2004).
Of great concern is the emergence of K. pneu-
moniae strains producing extended spectrum be-
ta-lactamases  (ESBLs).  ESBL  was  first  identified 
in Western Europe (France and Germany) in the 
mid-1980s (Gagliotti et al., 2008) and is capable of 
hydrolyzing  oxyimino-cephalosporins  and  inhib-
ited by β-lactamase inhibitors. These enzymes are 
not active against carbapenems (Ullah et al., 2009). 
Until  now,  because  of  mutations,  more  than  70 1340 DEANA MEDIĆ ET AL.
ESBLs have been described and most of them are 
members of the TEM-1, TEM-2 and SHV-1 family 
of enzymes (Mumtaz et al., 2011). During the past 
decade, a CTX-M-type of ESBLs has emerged in 
many countries worldwide, and it is the most com-
monly found in Enterobacteriaceae (Mirzaee et al., 
2009). The presence of ESBL-producing isolates is 
an indicator of the selective pressure of 3rd genera-
tion of cephalosporins, which are extensively used 
in hospitals.
Bloodstream infections caused by ESBL-produc-
ing bacteria have been associated with longer, more 
costly hospital stays and high mortality rates (Nwa-
dioha et al., 2010; Velaphi et al., 2009).
The  plasmid  encoding  ESBLs  frequently  also 
encodes a resistance to other antimicrobial classes, 
such as fluoroquinolones, aminoglycosides, trimeth-
oprim-sulfamethoxazole, leaving few therapeutic op-
tions available for treatment (Mumtaz et al., 2011).
Carbapenems, which are stable to most of the 
prevalent beta-lactamases, including ESBLs, are con-
sidered the agents of choice for treatment of serious 
infections like bloodstream infections caused by mul-
tiresistant K. pneumoniae (Nadkarni et al., 2009).
A new group of class A beta-lactamases, known 
as KP-type carbapenemases, has been described in 
northeastern USA in 1996. They quickly spread and 
have often appeared in Israel and Greece and other 
European countries (Marschall et al., 2009; Wood-
ford et al., 2004; Giakkoupi et al., 2009; Samuelsen 
et al., 2009; Grundmann et al., 2011). These enzymes 
were serine carbapenemases KPC (Klebsiella pneumo-
niae carbapenemase). 
Since 2008, a novel metallo-beta-lactamase en-
coded by the blaNDM-1 gene produced by Enterobac-
teriaceae was named New Delhi metallo-beta lacta-
mase-1 (NDM-1) (Yong et al., 2009). The isolates 
producing this enzyme have been imported repeat-
edly into Europe from the Indian subcontinent, par-
ticularly the United Kingdom, but also into Canada, 
Japan,  Africa  and  Australia  (Rolain  et  al.,  2010). 
Most of them were resistant to all antibiotics, except 
polymyxins, tigecycline, aztreonam, and occasion-
ally certain aminoglycosides. NDM-1 producers are 
mainly K. pneumoniae strains (Grundmann et al., 
2011; Yong et al., 2009).
In  order  to  formulate  the  policy  of  empirical 
therapy in high-risk units where infections due to re-
sistant organisms are much higher, it is necessary to 
investigate the frequency of ESBL- and KPC-positive 
strains in hospitals.
This study was designed to investigate the prev-
alence  of  ESBL-producing  K.  pneumoniae  strains 
isolated from blood in children and their suscepti-
bility to antimicrobial drugs commonly used in the 
therapy.
MATERIALS AND METHODS
Study design and specimen types
The study was conducted at the Center for Microbi-
ology of the Institute of Public Health of Vojvodina 
Province,  Serbia.  Samples  of  blood  cultures  from 
children younger than 18 years of age hospitalized 
in various pediatric departments in the Institute of 
Health  Care  of  Children  and  Youth  of  Vojvodina 
Province, were collected from January 2009 to De-
cember  2010.  During  the  two-year  study  period, 
5397 blood samples were processed: 2565 samples in 
2009. and 2832 in 2010. A total of 50 non-duplicate 
strains of K. pneumoniae were isolated.
Microbiological methods
All blood samples were routinely cultured in pedi-
atric  blood  culture  bottles  (BioMérieux,  Marcyl’ 
Etoile,  France)  using  a  semi-automated  blood-
culture  system  (BacT/Alert,  BioMérieux,  Marcyl’ 
Etoile, France). The positive samples were inocu-
lated onto blood agar and MacConkey agar plates 
(HiMedia,  India)  that  were  incubated  aerobically 
for 24 h at 37ºC. Isolation and identification of the 
causative  organisms  were  performed  by  standard 
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Antimicrobial susceptibility testing
Susceptibility to antimicrobial agents was tested by 
standard  disk-diffusion  on  Mueller-Hinton  agar 
(HiMedia, India) using antibiotic discs BioRad, USA. 
The performance and interpretation were based on 
the  recommendations  of  the  Clinical  Laboratory 
Standards Institute (CLSI, 2009; CLSI, 2010).
The  following  antimicrobial  agents  were  test-
ed:  ampicillin,  cefalotin,  ceftriaxone,  ceftazidime, 
amoxicillin/clavulanic acid, piperacillin/tazobactam, 
meropenem,  imipenem,  ertapenem,  gentamicin, 
amikacin,  co-trimoxazole  and  ciprofloxacin.  Es-
cherichia  coli  American  Type  Culture  Collection 
(ATCC)  25922  and  Staphylococcus  aureus  ATCC 
25923 were used for quality controls.
Detection of extended spectrum beta lactamases 
(ESBL) production
The initial screening and phenotypic confirmatory 
test were recommended by the CLSI (CLSI, 2009; 
CLSI, 2010). In this test, a disc of amoxicillin/clavu-
lanic acid was placed in center of the Petri dish al-
ready inoculated with the test microorganism, while 
cefotaxime, ceftazidime and ceftriaxone discs were 
placed at a distance of 20-25 mm (center-to-center) 
from the amoxicillin/clavulanic acid disc on the same 
plate. After incubation of 18-24 h at 37ºC, zones of 
inhibition around the 3rd generation cephalosporin 
discs were observed. The microorganism was labeled 
as ESBL-positive if the zone of inhibition around one 
or more cephalosporin discs was extended on the 
side nearest to the amoxicillin/clavulanic acid.
The  double-disk  synergy  test  was  used  as  the 
phenotypic confirmatory test, where the tested bac-
teria were inoculated on Mueller-Hinton agar and 
discs of cefotaxime and ceftazidime separately, and 
each of these in combination with clavulanic acid 
were placed on the surface of the plate. The micro-
organism was considered a ESBL-positive isolate if 
there was a difference of ≥5mm between the zones 
of inhibition of a single antibiotic and the disc with 
combination of antibiotic and clavulanic acid (CLSI, 
2009; CLSI, 2010). 
Statistical analysis
The  results  were  analyzed  using  SPSS  (Statistical 
Package for the Social Sciences) for Windows. The 
chi-square (χ2) test was used to compare associa-
tions between proportions and p values <0.05 were 
considered significant. 
RESULTS
K. pneumoniae was the second leading isolated mi-
croorganism,  and  the  first  among  Gram-negative 
isolates out of the total 424. The frequency of isola-
tion of K. pneumoniae was 12.2% (27 of 222 isolates) 
in 2009 and 11.3% (23 of 202 isolates) in 2010. There 
was a high frequency of ESBL-producing K. pneumo-
niae in both years: 70.4% (19 out of 27) and 82.6% 
(19 out of 23) in 2009 and 2010, respectively. Despite 
the increase of incidence, the difference was not sta-
tistically significant.
The results of our study show that resistance to 
aminoglycosides (gentamicin and amikacin) and co-
trimoxazole decreased in 2010 compared to 2009, 
while for ciprofloxacin stayed unchanged.
Resistance to piperacillin/tazobactam increased 
from 21.1% to 78.9% from 2009 to 2010, and the 
difference was statistically significant (p<0.05), and 
amoxicillin/clavulanic acid resistance also increased 
from 78.9% to 84.2%, but the difference was not sta-
tistically significant (p>0.05). 
Among the ESBL-producing strains, a total of 
17  isolates  (44.7%)  were  multidrug  resistant.  The 
most common MDR pattern was resistance to beta-
lactams, aminoglycosides and co-trimoxazole. 
Resistance  to  the  antibiotics  tested,  except 
carbapenems,  was  higher  in  the  ESBL-producing 
strains compared to the non-ESBL-producing bac-
teria. 1342 DEANA MEDIĆ ET AL.
table 1. In vitro resistance to antimicrobials of ESBL-positive and ESBL-negative K. pneumoniae strains isolated from blood in 2009.
ANTIBIOTIC
ESBL + (No=19) ESBL - (No=8)
Sensitive
(%)
Resistant
(%)
Sensitive
(%)
Resistant
(%)
Ampicillin 0 (0) 19 (100) 0 (0) 8 (100)
Cefazolin 0 (0) 19 (100) 3 (37.5)  5 (62.5)
Ceftriaxone 0 (0) 19 (100) 4 (50) 4 (50)
Ceftazidime 0 (0) 19 (100) 4 (50) 4 (50)
Piperacillin/tazobactam 15 (78.9) 4 (21.1) 6 (75) 2 (25)
Amoxicillin/clavulanic acid 4 (21.1) 15 (78.9) 4 (50) 4 (50)
Imipenem 19 (100) 0 (0) 8 (100) 0 (0)
Meropenem 19 (100) 0 (0) 8 (100) 0 (0)
Ertapenem 19 (100) 0 (0) 8 (100) 0 (0)
Gentamicin 0 (0) 19 (100) 4 (50) 4 (50)
Amikacin 9 (47.4) 10 (52.6) 6 (75) 2 (25)
Co-trimoxazole 7 (36.8) 12 (63.2) 4 (50) 4 (50)
Ciprofloxacin 16 (84.2) 3 (15.8) 6 (75) 2 (25)
table 2. In vitro resistance to antimicrobials of ESBL-positive and ESBL-negative K. pneumoniae strains isolated from blood in 2010.
ANTIBIOTIC
ESBL + (No=19) ESBL - (No=4)
Sensitive 
(%)
Resistant 
(%)
Sensitive 
(%)
Resistant 
(%)
Ampicillin 0 (0) 19 (100) 0 (0) 4(100)
Cefazolin 0 (0) 19  (100) 2 (50) 2 (50)
Ceftriaxone 0 (0) 19 (100) 3 (75) 1 (25)
Ceftazidime 0 (0) 19 (100) 3 (75) 1 (25)
Piperacillin/tazobactam 4 (21.1) 15 (78.9) 3 (75) 1 (25)
Amoxicillin/clavulanic acid 3 (15.8) 16 (84.2) 3 (75) 1 (25)
Imipenem 19 (100) 0 (0) 4 (100) 0 (0)
Meropenem 19 (100) 0 (0) 4 (100) 0 (0)
Ertapenem 19 (100) 0 (0) 4 (100) 0 (0)
Gentamicin 1 (5.3) 18 (94.7) 2 (50) 2 (50)
Amikacin 12 (63.2) 7 (36.8) 3 (75) 1 (25)
Co-trimoxazole 15 (78.9) 4 (21.1) 2 (50) 2 (50)
Ciprofloxacin 16 (84.2) 3 (15.8) 2 (50) 2 (50)BLOODSTREAM INFECTIONS IN CHILDREN 1343
All  ESBL-producing  isolates  were  sensitive  to 
carbapenems, which included imipenem, meropen-
em and ertapenem, in both years of investigation. 
Resistance to antimicrobial drugs during the two-
year period is given in Table 1 and Table 2.
ESBL-producing K. pneumoniae was most com-
monly isolated in the pediatric intensive care unit 
(PICU) of the Institute of Health Care of Children 
and Youth of Vojvodina Province.
The finding of ESBL-producing isolates in each 
ward of the Institute is shown in Table 3.
For the purposes of the study, patients were di-
vided into different age groups: group I – patients 
from 0 to 12 months (n=43, 86%), group II – patients 
from 13 to 24 months of age (n=4, 8%), group III 
– patients from 25 to 36 months of age (n=0, 0%) 
and group IV – patients from 37 to 48 months of 
age (n=3, 6 %). The majority of ESBL-producing K. 
pneumoniae was found in the first group. A total of 
55.3% of the patients were female, but the difference 
was not statistically significant according to the gen-
der (p value >0.05).
DISCUSSION
According to our results, K. pneumoniae was found 
to be the second most common etiological agent of 
bloodstream infections in children, and the first lead-
ing agent in the group of gram-negative bacteria. The 
frequency of isolation of K. pneumoniae was 12.2% (27 
of 222 isolates) in 2009 and 11.3% (23 of 202 isolates) 
in 2010. The prevalence of the pathogen observed was 
in accordance with other authors. In the Iranian study 
by Mamishi, K. pneumoniae was the most frequently 
isolated from blood cultures in children. The author 
found that the frequency of K. pneumoniae was 8.5% 
(Mamishi et al., 2005). Similar data were reported by 
Ben Jaballah in Tunisia and Almuneef in Saudi Ara-
bia (Ben Jaballah et al., 2006; Almunnef et al., 2005).
table 3. ESBL-positive and ESBL-negative K. pneumoniae isolates in various pediatric wards 
WARD
2009 2010 Total
ESBL+
(%)
ESBL-(%)
ESBL+
(%)
ESBL-(%)
ESBL+
(%)
ESBL-(%)
Pediatric Surgery 2 (10.5) 1 (12.5) 2 (10.5) 1 (25) 4 (10.5) 2 (16.7)
Pediatric Intensive 
Care Unit (PICU)
15 (79) 5 (62.5) 7 (36.8) 2 (50) 22 (57.9) 7 (58.3)
Other 2 (10.5) 2 (25) 10 (52.7) 1 (25) 12 (31.6) 3 (25)
Total 19 (100) 8 (100) 19 (100) 4 (100) 50 (100)
table 4. Demographic characteristics of patients with bloodstream infection caused by ESBL producing Klebsiella pneumoniae during 
2009-2010.
VARIABLES ESBL + (%) ESBL – (%) Total (%)
Sex
Male 17 (44.7) 8 (66.7) 25 (50)
Female 21 (55.3) 4 (33.3) 25 (50)
Age group
(months)
0-12 35 (92.1) 8 (66.6) 43 (86)
13-24 2 (5.3) 2 (16.7) 4 (8)
25-36 0 (0) 0 (0) 0 (0)
37-48 1 (2.6) 2 (16.7) 3 (6)1344 DEANA MEDIĆ ET AL.
ESBL-producing organisms are becoming in-
creasingly  common  worldwide,  and  represent 
an emerging infection threat (Kader and Kumar, 
2005). Recent studies have revealed that patients 
with septicemia caused by ESBL-producing organ-
isms had significantly a higher fatality rate than 
those with non-ESBL isolates (Mehrgan and Rah-
bar, 2008). Our study shows an increase of ESBL-
producers. The percentage of ESBL-producing K. 
pneumoniae was high in both years: 70.4% (19 out 
of 27) and 82.6% (19 out of 23) in 2009 and 2010 
respectively. Despite the increase of incidence, this 
difference was not statistically significant (p value 
>0.05).
ESBL prevalence varies in different countries. In 
some European countries, such as France, the fre-
quency of ESBL-producing K. pneumoniae is below 
5% (Raymond et al., 2007).
Even in pediatric institutions in the USA, ES-
BL-producing organisms are an emerging problem. 
The prevalence of ESBL-producing K. pneumoniae 
in pediatric bloodstream infections in the USA was 
between 18-52.9%. The same results were found in 
Korea (Blaschke et al., 2009).
Thirty percent of the K. pneumoniae were ESBL-
producing strains in the Grisaru-Soen study reported 
from Israel (Grisaru-Soen et al., 2007). Recent stud-
ies from Africa have reported a 33.3% prevalence of 
ESBL-producing  K.  pneumoniae  in  Ethiopia  (Seid 
and Asrat, 2005).
In our study incidence was much higher than re-
ported in these studies. 
Similar findings have been reported from Tunisia 
by Ben Jaballah, who found that 87.5% K. pneumo-
niae were ESBL-positive, and the rate of 86.6% was 
found by Malkan Rad in an Iranian hospital (Ben Ja-
balah et al., 2006; Rad and Momtazmanesh, 2004). 
Among the ESBL-producing strains in our study, a 
total of 17 isolates (44.7%) were multidrug resistant 
(MDR). Our results show a much lower frequency 
than those of Ben Jaballah, who found that MDR K. 
pneumoniae strains were detected in 85% of the cases 
(Ben Jaballah et al., 2006).
The most prevalent ESBL-producing K. pneumo-
niae was isolated from pediatric patients in the PICU 
ward of the Hospital, which is in accordance with 
Grisaru-Soen  and  many  others  studies  (Grisaru-
Soen et al., 2007).
Resistance to other antimicrobial drugs among 
ESBL-producing  K.  pneumonia  was  commonly 
found.
Gentamicin susceptibility was low among these 
isolates and this antibiotic should be used with cau-
tion when treating empirically. Resistance to gen-
tamicin was higher than to amikacin. Malkan Rad 
reported similar findings for resistance to amikacin 
(Rad and Momtazmanesh, 2004). 
Resistance  to  co-trimoxazole  significantly  de-
creased  in  2010  in  compared  to  2009  (p  value 
<0.05).
Ciprofloxacin is not routinely recommended for 
pediatric use, except in special cases where the ben-
efit outweighs the short-term risk of joint toxicity. 
Ciprofloxacin showed around 80% effectiveness to-
wards all bacterial isolates tested in this study. Simi-
lar results have been found in the Nwadioha study 
from  Kano  and  the  Zaoutis  study  from  the  USA 
(Nwadioha et al., 2010; Zaoutis et al., 2005).
The increase in resistance to amikacin and cipro-
floxacin in 2010 was not significant (p value>0.05).
In this study, a statistically significant increase 
of the resistance to piperacillin/tazobactam in 2010 
compared to the results in 2009, was found (p value 
<0.05),  while  resistance  to  amoxicillin/clavulanic 
acid was unchanged, around 80%.
Resistance to carbapenems was not found in this 
study. KPC-positive bacteria were present as a causa-
tive agent for bacteremia in a study by Aneja from 
Pittsburgh (Aneja et al., 2011). Carbapenem resist-BLOODSTREAM INFECTIONS IN CHILDREN 1345
ance is still rare in most countries. Some authors re-
ported emerging infections with a newly described 
carbapenem-resistant, so-called NDM-1-producing 
strains (Sidjabat et al., 2011). The presence of the 
carbapenem-resistant  K.  pneumoniae  NDM-1  in 
bloodstream infections was also confirmed by Roy 
from India and Mochon from the USA (Roy et al., 
2011; Mochon et al., 2011).
Carbapenems are widely used for the treatment 
of infections caused by MDR gram-negative bacte-
ria that produce extended-spectrum beta-lactamases 
(Zaoutis et al., 2005).
Several  investigators  have  concluded  that  the 
initial  treatment  of  bloodstream  infections  caused 
by  ESBL-producing  strains  with  non-carbapenem 
agents may be associated with higher mortality than 
treatment with a carbapenem agent (Yun-Kyung et 
al., 2002).
In conclusion, K. pneumoniae is the most com-
mon gram-negative bacterial isolate responsible for 
bloodstream  infections  in  pediatric  patients.  Our 
study shows a very high prevalence of ESBL-produc-
ing K. pneumoniae among hospitalized children with 
bloodstream infections. According to our two-year 
surveillance data, it seems likely that the burden of 
ESBL-producing pathogens in pediatrics will contin-
ue to increase. We noted very high rates of resistance 
to all tested classes of antimicrobial agents, except 
carbapenems. Our data suggest that amikacin should 
be considered as a synergistic antibiotic for the treat-
ment of bloodstream infections, together with other 
antimicrobial drugs. The study also highlights the 
need for the continual surveillance and understand-
ing of factors associated with infections, which are 
essential  for  developing  containment  strategies  to 
prevent this organism becoming a common problem 
in pediatric hospitals.
A rational use of antibiotics, especially in this ten-
der age group, in order to achieve a relatively high-
level  antibiotic  activity  against  offending  bacterial 
organisms, is recommended. Further drug resistance 
surveillance is necessary in our hospitals, as well as 
the molecular characterization of ESBL isolates. An 
accurate and rapid detection of these pathogens is 
necessary for therapeutic considerations and for the 
implementation of infection control measures. 
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